Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study-Reference-Cited by-同舟云学术

Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study

Published:2019-01 Issue: Volume:27 Page:65-73
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Zivadinov Robert^ORCID,Medin Jennie,Khan Nasreen,Korn Jonathan R.,Chitnis Tanuja,Naismith Robert T.,Alvarez Enrique,Dwyer Michael G.,Bergsland Niels,Carl Ellen,Silva Diego,Weinstock-Guttman Bianca

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,General Medicine

Reference25 articles.

1. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial;Calabresi;Lancet Neurol.,2014

2. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis;Cohen;N. Engl. J. Med.,2010

3. Effect of fingolimod on brain volume loss in patients with multiple sclerosis;De Stefano;CNS Drugs,2017

4. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis;De Stefano;J. Neurol. Neurosurg. Psychiatry,2016

5. Establishing pathological cut-offs for lateral ventricular volume expansion rates;Dwyer;Neuroimage Clin.,2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brain Atrophy Is Substantially Accelerated in Neurological Wilson's Disease: A Longitudinal Study;Movement Disorders;2022-09-27

2. Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study;NeuroImage: Clinical;2021

3. Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?;Expert Review of Neurotherapeutics;2020-10-10

4. Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis;Multiple Sclerosis International;2020-06-15

5. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study;Journal of Comparative Effectiveness Research;2019-04